FDMT Overview
Upcoming Projects (FDMT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (FDMT)
-
Third View: Discussing the clinical data for 4D-150 and the design of the 4FRONT Phase 3 program presented at the 4D-150 Wet AMD Development Day.
Ticker: FDMT
Executed On: Nov 05, 2024 at 03:00 PM EST -
Second View: Discussing the clinical data for 4D-150 and the design of the 4FRONT Phase 3 program presented at the 4D-150 Wet AMD Development Day.
Ticker: FDMT
Executed On: Oct 03, 2024 at 03:00 PM EDT -
Discussing the clinical data for 4D-150 and the design of the 4FRONT Phase 3 program presented at the 4D-150 Wet AMD Development Day.
Ticker: FDMT
Executed On: Oct 02, 2024 at 08:00 AM EDT -
A Third View: Delving into the results from the Phase 2 PRISM clinical trial of intravitreal 4D-150 in patients with wet AMD.
Ticker: FDMT
Executed On: Aug 22, 2024 at 09:00 AM EDT -
A Second View: Delving into the results from the Phase 2 PRISM clinical trial of intravitreal 4D-150 in patients with wet AMD.
Ticker: FDMT
Executed On: Aug 21, 2024 at 08:00 AM EDT -
Delving into the results from the Phase 2 PRISM clinical trial of intravitreal 4D-150 in patients with wet AMD.
Ticker: FDMT
Executed On: Jul 24, 2024 at 11:30 AM EDT -
Discussing the recent interim results from the Phase 2 PRISM clinical trial of intravitreal 4D-150 in patients with wet AMD
Ticker: FDMT
Executed On: Feb 15, 2024 at 08:00 AM EST -
Discussing the current treatment landscape and the recently presented interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease
Ticker: FDMT
Executed On: Feb 01, 2024 at 02:00 PM EST -
Discussing the standard of care and the potential of 4D-150, a novel genetic medicine that utilizes 4DMT’s evolved and customized R100 vector for intravitreal delivery to the retina to treat wet AMD.
Ticker: FDMT
Executed On: May 10, 2023 at 12:00 PM EDT -
A second discussion on EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, FDMT, RHHBY, REGN
Executed On: Mar 03, 2023 at 12:30 PM EST -
Discussing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, FDMT, RHHBY, REGN
Executed On: Mar 01, 2023 at 05:30 PM EST -
Reviewing the phase 1/2 clinical trial results of 4D Molecular Therapeutics' 4D-150, a potential gene therapy for patients with wet-AMD
Tickers: FDMT, RHHBY, REGN
Executed On: Jan 24, 2023 at 02:00 PM EST
Upcoming & Overdue Catalysts (FDMT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (FDMT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
